Q2 2014 Depomed Earnings Conference Call (Live)
08/06/14 at 4:30 p.m. ET
Depomed is a specialty pharmaceutical company focused on pain and other central nervous system conditions. We currently market four FDA-approved products, Gralise®, Cambia®, Zipsor®, and Lazanda®. We actively seek to expand our product portfolio through in-licensing, acquiring or obtaining co-promotion rights to commercially available products or late-stage product candidates that could be marketed and sold effectively with our existing products through our sales and marketing capability. In addition, Depomed also has successfully developed and licensed its unique drug-delivery technology, Acuform®. This patented oral-delivery technology allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. We have licensed Acuform technology to six pharmaceutical partners and the technology is currently being used in four marketed drugs, including Gralise.
The following are abbreviated descriptions of our products:
Gralise® (gabapentin), a once-daily product for the management of postherpetic neuralgia, Cambia®(diclofenac potassium for oral solution) for acute treatment of migraine attacks with or without aura in adults 18 years of age or older, Zipsor® (diclofenac potassium) liquid filled capsules, a product for the treatment of mild to moderate acute pain in adults, and Lazanda® (fentanyl) nasal spray CII for the management of breakthrough pain in cancer patients, 18 years of age and older, who are already receiving and who are tolerant to regular opioid therapy for their underlying persistent cancer pain. See Important Safety Information for Gralise and the black box warnings for Cambia, Zipsor, and Lazanda.
|Upcoming and Recent Events||> MORE|
4:30 p.m. ET
11:30 a.m. ET
3:35 p.m. ET